title: [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym].
abstract: BACKGROUND
  In Mexico, the prevalence of Helicobacter pylori (H. pylori) infection is high. The bacterial eradication rate with the administration of antibiotic regimens recommended by international guidelines is not yet clear.
  
  
  OBJECTIVE
  To determine the eradication frequency of H. pylori infection in the adult Mexican population that underwent treatment with the conventional triple regimen.
  
  
  METHODS
  A cross-sectional study was carried out that evaluated the effectiveness of the triple regimen in individuals with confirmed infection that received consensual treatment and then underwent tests to corroborate eradication.
  
  
  RESULTS
  From a total of 249 potential case records, 26 did not meet the inclusion criteria. Two hundred and twenty-three patients were enrolled for analysis, 64,00% women and 36,00% men, with a mean age of 49,4 years (range 17-86). Comorbidities presented in 55,60% of the patients and 28,60% referred to chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs). Bacterial eradication with the triple regimen was 65,50% (146/223); of the 77 patients with no eradication, 11 received a quadruple regimen as second-line treatment resulting in bacterial eradication in 5/11 (45,45%) patients, for an overall eradication of 67,70%.
  
  
  CONCLUSIONS
  The eradication rate in our study population was suboptimal due to the probability of multiple factors that are difficult to identify, given the retrospective design of the study. A prospective and controlled evaluation of the recommended regimens needs to be carried out in order to determine their true effectiveness.
authors.affiliation: Departamento de Gastroenterología y Endoscopia Gastrointestinal, Centro Médico Issemym, Metepec, Méx, México. saraigh69@yahoo.com
authors.forename: M S
authors.initials: MS
authors.lastname: González-Huezo
authors.forename: A
authors.initials: A
authors.lastname: Rojas-Sánchez
authors.forename: A A
authors.initials: AA
authors.lastname: Rosales-Solís
authors.forename: R M
authors.initials: RM
authors.lastname: Miranda-Cordero
authors.forename: A
authors.initials: A
authors.lastname: Hinojosa-Ruiz
authors.forename: E
authors.initials: E
authors.lastname: Mejía-García
authors.forename: E G
authors.initials: EG
authors.lastname: Cruz-González
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents